NASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free TCON Stock Alerts $1.85 +0.03 (+1.65%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.82▼$1.9650-Day Range$1.71▼$12.6252-Week Range$1.59▼$36.80Volume54,919 shsAverage Volume330,714 shsMarket Capitalization$4.22 millionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get TRACON Pharmaceuticals alerts: Email Address TRACON Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside3,143.2% Upside$60.00 Price TargetShort InterestHealthy32.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.00) to ($5.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.82 out of 5 stars 3.3 Analyst's Opinion Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted32.67% of the outstanding shares of TRACON Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTRACON Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TRACON Pharmaceuticals has recently decreased by 60.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCON. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 21 people have searched for TCON on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.61% of the stock of TRACON Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TRACON Pharmaceuticals are expected to decrease in the coming year, from ($4.00) to ($5.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About TRACON Pharmaceuticals Stock (NASDAQ:TCON)TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.Read More TCON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCON Stock News HeadlinesApril 16, 2024 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.comApril 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation UpdateApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 10, 2024 | uk.investing.comTRACON announces 1-for-20 reverse stock splitApril 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 8, 2024 | marketwatch.comShares of Tracon Pharmaceuticals Tumble 22% on Reverse SplitApril 8, 2024 | finanznachrichten.deTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock SplitApril 8, 2024 | globenewswire.comTRACON Pharmaceuticals Announces Reverse Stock SplitApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.April 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial OutlookApril 3, 2024 | msn.comTracon Pharma drops after pivotal data for cancer drugApril 3, 2024 | finance.yahoo.comTRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as PlannedMarch 13, 2024 | markets.businessinsider.comJonesTrading Reaffirms Their Hold Rating on TRACON Pharmaceuticals (TCON)March 8, 2024 | markets.businessinsider.comBuy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical TrialsMarch 7, 2024 | finanznachrichten.deTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 7, 2024 | seekingalpha.comTRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | globenewswire.comTRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 4, 2024 | msn.comTracon Q4 2023 Earnings PreviewMarch 4, 2024 | benzinga.comA Preview Of TRACON Pharma's EarningsFebruary 28, 2024 | globenewswire.comTRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024February 13, 2024 | finance.yahoo.comTRACON Pharmaceuticals, Inc. (TCON)December 23, 2023 | benzinga.comTRACON Pharma Stock (NASDAQ:TCON), Guidance and ForecastDecember 21, 2023 | markets.businessinsider.comBuy Rating for TRACON Pharmaceuticals on Envafolimab’s Promising Trial Outcomes and Strong Market PotentialNovember 25, 2023 | seekingalpha.comTCON TRACON Pharmaceuticals, Inc.November 21, 2023 | msn.comWhy Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?November 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON), Anavex Life Sciences (AVXL) and Genmab (GMAB)See More Headlines Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCON CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+3,143.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,590,000.00 Net MarginsN/A Pretax Margin-29.79% Return on Equity-10.25% Return on Assets7.86% Debt Debt-to-Equity RatioN/A Current Ratio0.89 Quick Ratio0.89 Sales & Book Value Annual Sales$12.05 million Price / Sales0.35 Cash Flow$1.61 per share Price / Cash Flow1.15 Book Value($0.37) per share Price / Book-5.00Miscellaneous Outstanding Shares2,280,000Free Float2,155,000Market Cap$4.22 million OptionableNo Data Beta0.94 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Charles P. Theuer M.D. (Age 60)Ph.D., Chairman, CEO & President Comp: $646.6kMr. Ya HuangExecutive Director of Statistical ProgrammingKey CompetitorsFinch Therapeutics GroupNASDAQ:FNCHKiromic BioPharmaNASDAQ:KRBPPalisade BioNASDAQ:PALIGamida CellNASDAQ:GMDAQFresh Tracks TherapeuticsNASDAQ:FRTXView All CompetitorsInsidersCharles TheuerBought 199 shares on 4/26/2023Total: $2,626.80 ($13.20/share)View All Insider Transactions TCON Stock Analysis - Frequently Asked Questions Should I buy or sell TRACON Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TCON shares. View TCON analyst ratings or view top-rated stocks. What is TRACON Pharmaceuticals' stock price target for 2024? 3 brokers have issued twelve-month price targets for TRACON Pharmaceuticals' stock. Their TCON share price targets range from $60.00 to $60.00. On average, they expect the company's share price to reach $60.00 in the next year. This suggests a possible upside of 3,143.2% from the stock's current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts. How have TCON shares performed in 2024? TRACON Pharmaceuticals' stock was trading at $3.5020 at the beginning of the year. Since then, TCON stock has decreased by 47.2% and is now trading at $1.85. View the best growth stocks for 2024 here. Are investors shorting TRACON Pharmaceuticals? TRACON Pharmaceuticals saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 744,900 shares, a decrease of 60.8% from the March 15th total of 1,900,000 shares. Based on an average daily volume of 3,400,000 shares, the days-to-cover ratio is presently 0.2 days. View TRACON Pharmaceuticals' Short Interest. When is TRACON Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TCON earnings forecast. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) issued its earnings results on Tuesday, March, 5th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of ($0.60) by $0.80. The biopharmaceutical company had revenue of $3.41 million for the quarter, compared to analyst estimates of $3 million. When did TRACON Pharmaceuticals' stock split? TRACON Pharmaceuticals shares reverse split on the morning of Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX). When did TRACON Pharmaceuticals IPO? TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCON) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.